InMed Pharmaceuticals Inc (NASDAQ: INM) is -6.75% lower on its value in year-to-date trading and has touched a low of $0.12 and a high of $2.08 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The INM stock was last observed hovering at around $0.40 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.39, the stock is 71.97% and 57.22% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.84 million and changing -3.94% at the moment leaves the stock 21.21% off its SMA200. INM registered -52.17% loss for a year compared to 6-month loss of -7.64%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 74.34% gain in the last 1 month and extending the period to 3 months gives it a 38.54%, and is -7.64% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 19.14% over the week and 19.01% over the month.
InMed Pharmaceuticals Inc (INM) has around 13 employees, a market worth around $1.29M and $5.63M in sales. Profit margin for the company is -108.01%. Distance from 52-week low is 221.38% and -81.35% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.36%).
InMed Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at 0.0 with sales reaching $1.79M over the same period., but quarterly earnings will post 31.00% year-over-year. Quarterly sales are estimated to shrink -22.60% in year-over-year returns.
13.0 institutions hold shares in InMed Pharmaceuticals Inc (INM), with institutional investors hold 3.13% of the company’s shares. The shares outstanding are 3.33M, and float is at 3.29M with Short Float at 1.14%. Institutions hold 3.11% of the Float.
The top institutional shareholder in the company is SABBY MANAGEMENT, LLC with over 0.31 million shares valued at $81571.0. The investor’s holdings represent 3.1961 of the INM Shares outstanding. As of 2024-06-30, the second largest holder is VIRTU FINANCIAL LLC with 86684.0 shares valued at $23000.0 to account for 0.9017 of the shares outstanding. The other top investors are XTX TOPCO LTD which holds 17819.0 shares representing 0.1854 and valued at over $4731.0, while HRT FINANCIAL LP holds 0.1664 of the shares totaling 15996.0 with a market value of $4000.0.
InMed Pharmaceuticals Inc (INM) Insider Activity
The most recent transaction is an insider sale by MANCINI ALEXANDRA DIANE JANET, the company’s Consultant. SEC filings show that MANCINI ALEXANDRA DIANE JANET sold 240 shares of the company’s common stock on Jul 31 ’24 at a price of $0.18 per share for a total of $42.0. Following the sale, the insider now owns 0.0 shares.
InMed Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 21 ’24 that HULL ANDREW (Director) bought a total of 37,500 shares of the company’s common stock. The trade occurred on Feb 21 ’24 and was made at $0.39 per share for $14625.0. Following the transaction, the insider now directly holds 38258.0 shares of the INM stock.
Still, SEC filings show that on Feb 20 ’24, ADAMS ERIC A (President & CEO) acquired 41,600 shares at an average price of $0.36 for $14922.0. The insider now directly holds 43,959 shares of InMed Pharmaceuticals Inc (INM).
